Obexelimab Reduces Disease Flares and Steroid-Toxicity in IgG4-RD
An exciting Phase 3 trial has confirmed that obexelimab significantly reduces the risk of disease flare in IgG4-related disease (IgG4-RD) while also delivering measurable reductions in ...
Steroid-Sparing Is Not Enough: GCA Trials Need Toxicity Data
New phase 3 data from the GCAptAIN trial show that secukinumab enabled a shorter steroid taper, less exposure, and meaningfully lower steroid-toxicity in giant cell arteritis (GCA). Although the ...
Secukinumab Delivers Sustained Remission and Toxicity Reduction in PMR
For the majority of patients with polymyalgia rheumatica, glucocorticoids do not provide a durable solution. They induce remission, but they do not maintain it. REPLENISH, the largest PMR clinical ...
Six Months on Steroids: The Point at Which Toxicity Becomes Undeniable
A new prospective study published in Seminars in Arthritis and Rheumatism confirms what clinicians have long known but have been unable to quantify: steroid-toxicity is universal in patients on ...
Why Steroid Dose Alone Cannot Define Steroid-Sparing Value in Asthma Development
Approximately 13 million people worldwide have severe, uncontrolled asthma even with optimized treatment, according to the Global Initiative for Asthma (GINA). In this population, systemic steroid ...
Curious about the true cost of steroid-toxicity?
Download our infographic today
